1NP1.F Flerie AB (publ)

Healthcare Biotechnology Frankfurt Exchange
1.08 EUR
Close of Nov 11, 2026
1.03 3.16
Market cap
EUR 96.1M
P/E
-
P/B
0.34x
ROE
-18.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1NP1.F undervalued?

Graham number

The Graham number of Flerie AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Flerie AB (publ) fundamental analysis

No fundamental analysis for Flerie AB (publ) yet.

Flerie AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Flerie AB (publ)

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.

Full company profile